Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OxyContin Will Face Fewer Generics Following Patent Infringement Settlement

This article was originally published in The Pink Sheet Daily

Executive Summary

As part of settlement agreements with Purdue Pharma, Endo and Teva agree to stop selling generic versions of the pain medication.
Advertisement

Related Content

OxyContin Patent Settlement Could Mean No Generics Come 2008
OxyContin Patent Settlement Could Mean No Generics Come 2008
Endo To Launch Opana ER Oxymorphone With Two Risk Management Programs
Risky Business: Appellate Decision Returns Endo's Generic OxyContin Case To Trial Court
Endo's Generic OxyContin To Launch Following Patent Invalidation
Endo's Generic OxyContin To Launch Following Patent Invalidation

Topics

Advertisement
UsernamePublicRestriction

Register

PS064762

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel